OptumRx's Jon Mahrt Discusses Irresponsible Drug Pricing for Products With Multiple Indications

When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.

Related Keywords

United States ,Nevada ,American ,Jon Mahrt ,Las Vegas ,Senate Committee On Health ,Novo Nordisk ,American Journal ,Asembia Specialty Pharmacy Summit ,Inflation Reduction Act ,Senate Committee ,Inflation Reduction ,Drug Pricing ,Glp 1 ,